Merck KGaA Is Latest Partner For C4 Therapeutics’ Protein Degradation

New deal shows growing big pharma interest in protein degradation, with C4 expecting multiple in-house updates this year.

C4 Therapeutics is on a roll in finding partners to advance its protein degradation platform, signing a deal with Merck KGaA to develop two oncology assets.

The collaboration will center on two preclinical targeted protein degraders against critical oncogenic proteins, and C4 Therapeutics will receive an...